Bayer (BAYRY) has confirmed its currency-adjusted Group outlook for 2025. The company now expects sales growth and the EBITDA margin before special items at the Pharmaceuticals Division to come in at the upper end of the range given in the Annual Report 2024. In view of developments with respect to the legal risks, Bayer expects the special items in both EBIT and EBITDA to come in at the upper end of the range given in the guidance. The company is continuously evaluating the impacts of the current geopolitical developments, especially in relation to potential tariffs. Based on current calculations of the financial effects, Bayer does not see a need to revise the full-year guidance. However, there is considerable uncertainty concerning the future impacts of any potential further developments in relation to this issue, as well as with respect to exchange-rate developments.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer reports Q1 core EPS EUR 2.49 vs. EUR 2.82 last year
- Bayer to reorganize Crop Science vision in Germany, cut hundreds of jobs
- BAYRY Earnings this Week: How Will it Perform?
- Bayer’s treatment of Alport syndrome granted FDA orphan designation
- Bayer price target lowered to EUR 20 from EUR 22 at HSBC
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue